View all news

RVPH: FDA Feedback on New Formulation Imminent

11/17/2026

By John Vandermosten, CFA

OTCQB: RVPH

READ THE FULL RVPH RESEARCH REPORT

Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) reported third quarter 2026 results on November 13th, 2026. Earlier this year, Reviva engaged with the FDA seeking feedback regarding a formulation change for brilaroxazine to be used in its second RECOVER trial. The company expects a response from the agency in 4Q:26. If the agency consents, management has indicated that Reviva will conduct a 30-patient bioequivalence study using the new formulation to ensure comparability of the new formulation. It will then begin the Phase III RECOVER II study. If these steps are successful, patient enrollment is anticipated in 2Q:27 and trial completion approximately one year later. Additional capital will be required to begin. In support of the new formulation, Reviva has filed for a composition of matter patent for brilaroxazine that, if granted, may extend patent life and commercial exclusivity until 2046.

Operating and Financial Results

On November 13th, 2026, Reviva reported 3Q:26 financial and operating results and filed its Form 10-Q with the SEC. Reviva generated no revenues in 3Q:26 and posted an operating loss of $2.4 million, with expenses falling by 40% due to the completion of the RECOVER open label extension (OLE) study last year. For the quarter ending September 30th, 2026 and versus the corresponding prior year quarter:

  • Research & development expense totaled $1.2 million, down 44% from $2.1 million, with the change attributable to lower salaries and wages, stock-based compensation, external research and development costs partially offset by a slight rise in non-clinical consulting costs;
  • General & administrative expenses totaled $1.2 million, declining 35% from $1.9 million on account of reduced stock-based compensation, consultant and professional expenses, and legal expenses. Employee-related expenses and directors’ and officers’ insurance expenses remained relatively flat;
  • Other income of $136,000 compared to $22,000 with the difference attributable to higher interest income partially offset by a loss on remeasurement of warrant liabilities and other expense;
  • Provision for taxes was $2,000 related to payment of state and foreign taxes;
  • Net loss was $2.3 million vs $4.0 million, or $0.17 and $1.09 per share, respectively.[1]

As of September 30th, 2026, Reviva held $17.5 million in cash on its balance sheet. Cash burn for the first nine months of 2026 was $8.1 million while cash flows from financing were $11.1 million. Financing transactions from a public offering and an ATM facility were slightly offset by repayment of short-term debt. Reviva notes in its 3Q:26 10-Q filing that it does not have sufficient cash to support operations for the next 12 months. Reviva sees sufficient cash to cover anticipated outlays until 3Q:27. However, this does not include the funds required to run the RECOVER II trial which will require a capital raise.

Summary

Reviva reported third quarter 2026 financial results listing $17.5 million of cash on the balance sheet. Earlier this year, Reviva reached out to the FDA seeking its feedback with respect to a new formulation of brilaroxazine in the RECOVER II trial. Management expects that the agency will respond in 4Q:26 after which it will begin a bioequivalence study using the new formulation. It will then begin the Phase III RECOVER II study. Reviva will require additional capital to begin the Phase III work. Based on our conversations with management, we think the trial will take about a year to complete after the first enrollment.

In support of its new formulation, Reviva has filed for a composition of matter patent with the USPTO and asked for accelerated review. If granted, the patent would extend intellectual property rights and commercial exclusivity for brilaroxazine until 2046, dramatically extending the life of the formulation used in RECOVER II. The company will need to both gain the FDA’s agreement on using the new formulation and convince investors to contribute new capital before the trial can begin. We have confidence in brilaroxazine’s safety and efficacy relative to other atypical antipsychotics but recognize the difficult funding environment that Reviva faces.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

________________________

[1] We adjust prior year earnings per share using a 1:20 reverse stock split effective March 9th, 2026.

Multimedia Files:

Categories: Press Releases
View all news